GlassScriptPhysician profile
Sukhpal I Jassi
NPI 1649205238
$5,065.16
in general payments reported to CMS, 2019-2025
29 companies · $939 in 2025
The $939 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $790 · 2020: $467 · 2021: $663 · 2022: $734 · 2023: $624 · 2024: $848 · 2025: $939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,411.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $861.84 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $568.25 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $506.27 | 2019-2025 | Jardiance |
| Pfizer INC. | $467.54 | 2019-2025 | |
| Glaxosmithkline, LLC. | $365.56 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $332.06 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Corcept Therapeutics | $257.99 | 2024-2025 | Korlym |
| Amarin Pharma, INC. | $244.07 | 2019-2023 | |
| Amgen INC. | $213.77 | 2019-2025 | Repatha, Otezla, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $167.85 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $161.40 | 2019-2023 | Xarelto |
| Astellas Pharma US INC | $115.90 | 2019-2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $106.09 | 2019-2022 | |
| Abbvie INC. | $95.45 | 2022-2024 | |
| Esperion Therapeutics, INC. | $89.41 | 2024-2025 | Nexletol |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $79.84 | 2019-2022 | |
| Abbott Laboratories | $78.39 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.42 | 2019-2023 | Trulance, Xifaxan |
| Sanofi-Aventis U.S. LLC | $50.38 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $49.18 | 2022 | |
| Nevro Corp. | $41.14 | 2023-2024 | Senza |
| Biohaven Pharmaceuticals, INC. | $37.60 | 2021 | |
| Sanofi Pasteur INC. | $21.27 | 2023 | |
| Biogen, INC. | $20.41 | 2022 | |
| Horizon Therapeutics Plc | $19.66 | 2020 | |
| Phathom Pharmaceuticals, INC. | $18.52 | 2024 | Voquezna |
| Jazz Pharmaceuticals INC. | $17.69 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.93 | 2022 | |
| Ironwood Pharmaceuticals, INC | $11.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sukhpal Jassi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.